Interferon-γ augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis

American Journal of Pathology

Volumn 161, Issue 4, 2002, Pages 1485-1495

  Li, Jie Hui ^a   Kluger, Martin S ^a   Madge, Lisa A ^a   Zheng, Lian ^a   Bothwell, Alfred L M ^a   Pober, Jordan S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTIBODY; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 8; CASPASE INHIBITOR; CELL SURFACE PROTEIN; CYCLOHEXIMIDE; FAS ANTIGEN; GAMMA INTERFERON; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN SYNTHESIS INHIBITOR;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SENSITIZATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VASCULAR ENDOTHELIUM;

EID: 0036790530     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64424-0     Document Type: Article

References (53)

1. Nagata S, Golstein P: The Fas death factor. Science 1995, 267:1449-1456
2. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243
3. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178
4. Debatin KM, Goldmann CK, Bamford R, Waldmann TA, Krammer PH: Monoclonal-antibody-mediated apoptosis in adult T-cell leukemia. Lancet 1990, 335:497-500
5. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP: Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999, 17:331-367
6. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95(Fas/APO-1) death-inducing signaling complex. Cell 1996, 85:817-827
7. Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996, 85:803-815
8. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J: Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195
9. Krueger A, Baumann S, Krammer PH, Kirchhoff S: FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001, 21:8247-8254
10. Yeh WC, Itie A, Elia AJ, Ng M, Shu HB, Wakeham A, Mirtsos C, Suzuki N, Bonnard M, Goeddel DV, Mak TW: Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 2000, 12:633-642
11. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME: Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998, 17:1675-1687
12. Krammer PH: CD95's deadly mission in the immune system. Nature 2000, 407:789-795
13. Nagata S: Fas ligand-induced apoptosis. Annu Rev Genet 1999, 33:29-55
14. Nagata S: Apoptosis by death factor. Cell 1997, 88:355-365
15. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-incuced apoptosis as a mechanism of immune privilege. Science 1995, 270:1189-1192
16. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996, 184:1075-1082
17. Sata M, Luo Z, Walsh K: Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia. J Immunol 2001, 166:6964-6971
18. Pober JS, Cotran RS: Cytokines and endothelial cell biology. Physiol Rev 1990, 70:427-451
19. Karsan A, Harlan JM: Modulation of endothelial cell apoptosis: mechanisms and pathophysiological roles. J Atheroscler Thromb 1996, 3:75-80
20. Westlin WF, Gimbrone MAJ: Neutrophil-mediated damage to human vascular endothelium: role of cytokine activation. Am J Pathol 1993, 142:117-128
21. Richardson BC, Lalwani ND, Johnson KJ, Marks RM: Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur J Immunol 1994, 24:2640-2645
22. Sata M, Suhara T, Walsh K: Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy. Arterioscler Thromb Vasc Biol 2000, 20:309-316
23. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S: Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997, 186:2045-2050
24. Li JH, Rosen D, Sondel P, Berke G: Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells. Immunology 2002, 105:267-277
25. Sundararajan R, Cuconati A, Nelson D, White E: Tumor necrosis factor-α induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K. J Biol Chem 2001, 276:45120-45127
26. Scaffidi C, Schmitz I, Krammer PH, Peter ME: The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999, 274:1541-1548
27. Epperson DE, Pober JS: Antigen-presenting function of human endothelial cells: direct activation of resting CD8 T cells. J Immunol 1994, 153:5402-5412
28. Kluger MS, Johnson DR, Pober JS: Mechanism of sustained E-selectin expression in cultured human dermal microvascular endothelial cells. J Immunol 1997, 158:887-896
29. Zheng L, Dengler TJ, Kluger MS, Madge LA, Schechner JS, Maher SE, Pober JS, Bothwell AL: Cytoprotection of human umbilical vein endothelial cells against apoptosis and CTL-mediated lysis provided by caspase-resistant Bcl-2 without alterations in growth or activation responses. J Immunol 2000, 164:4665-4671
30. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S: Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 1994b, 6:1567-1574
31. Li JH, Rosen D, Ronen D, Behrens CK, Krammer PH, Clark WR, Berke G: The regulation of CD95 ligand expression and function in CTL. J Immunol 1998, 161:3943-3949
32. Walsh CM, Glass AA, Chiu V, Clark WR: The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J Immunol 1994, 153:2506-2504
33. Sata M, Walsh K: TNF-α regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998, 4:415-420
34. Hausler P, Papoff G, Eramo A, Reif K, Cantrell DA, Ruberti G: Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. Eur J Immunol 1998, 28:57-69
35. Youn BS, Kim YJ, Mantel C, Yu KY, Broxmeyer HE: Blocking of c-FLIP(L)-independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction. Blood 2001, 98:925-933
36. Suhara T, Mano T, Oliveira BE, Walsh K: Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ Res 2001, 89:13-19
37. Green DR, Ferguson TA: The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2001, 2:917-924
38. D'Alessio A, Riccioli A, Lauretti P, Padula F, Muciaccia B, De Cesaris P, Filippini A, Nagata S, Ziparo E: Testicular FasL is expressed by sperm cells. Proc Natl Acad Sci USA 2001, 98:3316-3321
39. Fulda S, Meyer E, Debatin KM: Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res 2000, 60:3947-3956
40. Panka DJ, Mano T, Suhara T, Walsh K, Mier JW: Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 2001, 276:6893-6896
41. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A: Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 2000, 60:5673-5680
42. Salvesen GS, Dixit VM: Caspase activation: the induced-proximity model. Proc Natl Acad Sci USA 1999, 96:10964-10967
43. Bender JR, Sadeghi MM, Watson C, Pfau S, Pardi R: Heterogeneous activation thresholds to cytokines in genetically distinct endothelial cells: evidence for diverse transcriptional responses. Proc Natl Acad Sci USA 1994, 91:3994-3998
44. McDouali RM, Batten P, McCormack A, Yacoub MH, Rose ML: MHC class II expression on human heart microvascular endothelial cells: exquisite sensitivity to interferon-γ and natural killer cells. Transplantation 1997, 64:1175-1180
45. Choi C, Xu X, Oh JW, Lee SJ, Gillespie GY, Park H, Jo H, Benveniste EN: Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Cancer Res 2001, 61:3084-3091
46. Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Kolesnick R, Gulbins E: CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 2001, 276:20589-20596
47. Jiang Y, Woronicz JD, Liu W, Goeddel DV: Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 1999, 283:543-546
48. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S: Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995, 154:3806-3813
49. Restifo NP: Countering the "counterattack" hypothesis. Nat Med 2001, 7:271-274
50. Tellides G, Tereb DA, Kirkiles-Smith NC, Kim RW, Wilson JH, Schechner JS, Lorber MI, Pober JS: Interferon-γ elicits arteriosclerosis in the absence of leukocytes. Nature 2000, 403:207-211
51. Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P: Interferon-γ deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997, 100:550-557
52. Salomon RN, Hughes CC, Schoen FJ, Payne DD, Pober JS, Libby P: Human coronary transplantation-associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol 1991, 138:791-798
53. Dong C, Wilson JE, Winters GL, McManus BM: Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest 1996, 74:921-931